Scarica l'app Stockscreener
68.31
0.29%
0.20
Dopo l'orario di chiusura:
68.51
0.20
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$68.11
Aprire:
$67.86
Volume 24 ore:
816.04K
Relative Volume:
0.66
Capitalizzazione di mercato:
$5.43B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-11.50
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+2.88%
1M Prestazione:
+11.31%
6M Prestazione:
+37.06%
1 anno Prestazione:
+71.12%
Intervallo 1D:
$67.56
$69.28
Intervallo di 1 settimana:
$66.00
$69.88
Portata 52W:
$35.95
$69.88
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
68.31 | 5.41B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Brighton Jones LLC Invests $226,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
Can PTC Therapeutics Inc. stock reach $100 price targetWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Published on: 2025-11-02 01:56:33 - newser.com
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investorsJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
How to read the order book for PTC Therapeutics Inc.July 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,088,787.00 in Stock - MarketBeat
Why PTC Therapeutics Inc. (BH3) stock is trending on social media2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-01 00:56:06 - newser.com
Insider Sell: Emma Reeve Sells 15,666 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics Inc expected to post a loss of $1.37 a shareEarnings Preview - TradingView
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares - Investing.com Australia
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares By Investing.com - Investing.com South Africa
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 69.53 USD By Investing.com - Investing.com Australia
PTC Therapeutics to Participate at Upcoming Investor Conferences - Barchart.com
How PTC Therapeutics Inc. stock compares to growth peers2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
PTC Therapeutics Inc. stock prediction for this weekWeekly Trend Recap & Low Risk Entry Point Guides - newser.com
Will PTC Therapeutics Inc. (BH3) stock attract long term capital inflowsJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Detecting support and resistance levels for PTC Therapeutics Inc.Rate Hike & Safe Entry Point Alerts - newser.com
PTC Therapeutics (NASDAQ:PTCT) NASDAQ Composite Leads Biotech - Kalkine Media
How to forecast PTC Therapeutics Inc. trends using time seriesWall Street Watch & Technical Entry and Exit Alerts - newser.com
Ptc Therapeutics stock hits 52-week high at 69.53 USD - Investing.com
Is PTC Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Setups & Verified Technical Signals - newser.com
How Recent Developments Are Shaping the PTC Therapeutics Investment Story - Yahoo Finance
PTC Therapeutics (PTCT) to Release Earnings on Tuesday - MarketBeat
Published on: 2025-10-29 06:46:31 - newser.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Allianz Asset Management GmbH - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.July 2025 Patterns & Weekly High Momentum Picks - newser.com
Jefferies Maintains PTC Therapeutics (PTCT) Buy Recommendation - Nasdaq
Huntington’s Disease | Clinical Landscape, Key Companies, Therapeutic Assessment, Treatment Algorithms, and Pipeline Insights – featuring leading players such as Hoffmann-La Roche, PTC Therapeutics, A - Barchart.com
PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com
Bevacizumab: Clinical Overview, Key Companies, Therapeutic Insights, Treatment Strategies, and Pipeline Analysis | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG B - Barchart.com
Published on: 2025-10-28 14:58:18 - fcp.pa.gov.br
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 - Insider Monkey
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Published on: 2025-10-28 05:32:46 - newser.com
24,679 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Convergence Investment Partners LLC - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):